Navigation Links
Shire plc: Strong Third Quarter and Increased Non GAAP Earnings Expectations
Date:10/24/2013

delivered double digit growth including VYVANSE(up 21% to $299 million), LIALDA/MEZAVANT (up 36% to $142 million), ELAPRASE® (up 17% to $129 million), VPRIV® (up 17% to $88 million), INTUNIV® (up 17% to $81 million) and FIRAZYR(up 107% to $63 million). LIALDA/MEZAVANTsales in Q3 2013 were particularly strong, primarily due to growth in US market share.

Growth in total product sales was moderated by DERMAGRAFT® (down 29% to $24 million), ADDERALL XR® (down 20% to $81 million) and REPLAGAL® (down 11% to $109 million). REPLAGAL product sales continue to be impacted by the return of competition to the Fabry market.

  • Total revenues were up 12% to $1,237 million (Q3 2012: $1,100 million) as the growth in product sales was partially offset by lower royalties.
  • On a Non GAAP basis:

Operating income was up 30% to $422 million (Q3 2012: $325 million), as total operating costs in Q3 2013 increased at a lower rate (up 5%) than total revenues (up 12%) demonstrating our focus on delivering efficient growth. Research and Development expenditure was up 2% and Selling, General and Administrative expenditure was up 1%.

On a US GAAP basis:

Operating income was up 25% to $341 million (Q3 2012: $273 million), a lower rate of increase than on a Non GAAP basis as Q3 2013 included higher acquisition and integration costs as compared to Q3 2012 and reorganization costs of $14 million not incurred in Q3 2012. Research and Development expenditure was up 2% and Selling, General and Administrative expenditure was up 1%.

  • Non GAAP diluted earnings per American Depository Share ("ADS") increased 30% to $1.77 (Q3 2012: $1.36) primarily due to higher Non GAAP operating income.

On
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
11. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 EPFL and the University of  ... of John P. Donoghue . The American neuroscientist ... . The new Wyss Center for ... Geneva , has named as its director ... P. Donoghue , founder of Brown University,s Institute for ...
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... July 10, 2014 Terascala, the industry ... that Alan Swahn, a former vice president of product ... as vice president of marketing. Terascala’s software when combined ... NetApp create the highest performance and most reliable solutions ... to guide Terascala’s channel expansion and broaden its product ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded for ... a second treatment cup to help prevent and smooth skin ... thinner on the edges for a softer contact with the ... surfaces on the face, neck and décolleté. Choose to use ... such as the cheeks and neck, or opt for the ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... /PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group Co., Inc. ... developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), ... nutritional products in the People,s Republic of China, today ... December 31, 2010. Fiscal 2010 Financial ...
... Although top bio-pharmaceutical companies agree that Key Opinion ... a new product, increasing competition has made it difficult ... role of Medical Science Liaisons (MSLs) in forging relationships ... years. In fact, today, MSL ...
... 2011 Reportlinker.com announces that a new market ... Global Angiongenesis Inhibitors and ... This report analyzes the ... in US$ Million by the following product ...
Cached Biology Technology:Weikang Bio-Technology Announces Fiscal 2010 Financial Results 2Weikang Bio-Technology Announces Fiscal 2010 Financial Results 3Weikang Bio-Technology Announces Fiscal 2010 Financial Results 4Weikang Bio-Technology Announces Fiscal 2010 Financial Results 5Weikang Bio-Technology Announces Fiscal 2010 Financial Results 6Weikang Bio-Technology Announces Fiscal 2010 Financial Results 7Newly Updated for 2011: Medical Science Liaison Study Shows Growth in KOL Outreach, Impact 2Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 2Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 3Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 4Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 5Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 6Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 7Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 8Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 9Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 10Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 11Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 12Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 13Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 14Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 15Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 16Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 17
(Date:7/10/2014)... and other major cities in New Mexico, nearly every ... wastewater rather than precious potable water supplies. Across the ... all golf courses receive treated effluent. Reusing the effluent ... golf courses and homeowners alike fertilize their lawns during ... nitrate. A New Mexico State University turfgrass expert has ...
(Date:7/10/2014)... Mass. , June 30, 2014  Aware, Inc. ... biometrics software and services, previously announced on June 26, ... special cash dividend of $1.75 per share, or approximately ... date of July 10, 2014 and a payment date ... by NASDAQ that it had set an ex-dividend date ...
(Date:7/10/2014)... 2014 It is a great honor for ... of the world-renowned Thoracic and Cardiovascular surgeon, Mark E ... Dr. Ginsburg, with over 34 years of experience, is ... Good Samaritan Regional Medical Center. Dr. Ginsburg has been ... and is considered an expert in the implantation of ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
... , BOSTON -- October 17, 2011-- In a paper published ... headed by Mary R. Loeken, PhD, has identified the enzyme AMP ... the risk of neural tube defects such as spina bifida and ... Even if women with diabetes -- either type 1 or ...
... polyester which occurs naturally in bacteria as Ralstonia ... PHB is biodegradable and is not dependent on fossil ... produce to replace petroleum-based plastics. New research reported in ... describes an alternative method of producing PHB in ...
... have found a way to inject a precise dose of ... without a needle. The technique uses electricity to "shoot" ... a cell in a fraction of a second. L. ... the technique in the online edition of the journal ...
Cached Biology News:Joslin study finds clue to birth defects in babies of mothers with diabetes 2Researchers do precise gene therapy without a needle 2Researchers do precise gene therapy without a needle 3
Tracker Datamatrix RS-1* reads 96 2D Bar-coded tubes within 20 seconds....
Request Info...
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C ... Cl N O 6 ,M.W.= ... ,Solution: Clear (2% in DMF) ,Biological ... and M13 ,Elemental Analysis: Agrees with ...
...
Biology Products: